IPRATROPIUM BROMIDE

Post-LOE

ipratropium bromide

ANDAINHALATIONSOLUTION
Approved
Sep 2001
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
8

Mechanism of Action

CLINICAL PHARMACOLOGY Ipratropium bromide is an anticholinergic (parasympatholytic) agent that, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released from the vagus nerve. Anticholinergics prevent the…

Clinical Trials (5)

NCT01943552Phase 4Completed

Ipratropium Bromide in Peri-Operative COPD

Started Oct 2013
192 enrolled
Pulmonary Disease, Chronic Obstructive
NCT00911651Phase 4Completed

Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients

Started Jun 2008
6 enrolled
COPD
NCT02177253Phase 3Completed

Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease

Started Oct 2002
1,118 enrolled
Pulmonary Disease, Chronic Obstructive
NCT02260011Phase 2Completed

Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease

Started Oct 2000
41 enrolled
Pulmonary Disease, Chronic Obstructive
NCT02236169Phase 2Completed

Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Started Oct 2000
30 enrolled
Pulmonary Disease, Chronic Obstructive